Reasons to Retain STE Stock in Your Portfolio Now

Core Insights - STERIS plc's growth in fiscal Q2 2025 is primarily driven by its Healthcare business and the positive outlook for its Applied Sterilization Technologies (AST) segment [1][2] Company Performance - The Healthcare segment reported a revenue growth of 9% year over year, with consumable revenues increasing by 12% and service revenues by 14%, attributed to higher procedure volumes in the U.S. and market share gains [4] - The AST division experienced a 9% reported growth year over year, driven by a 6% increase in service revenues and improved capital equipment revenues [5] - STERIS has a market capitalization of $21.15 billion and has consistently surpassed earnings estimates over the past four quarters, with an average surprise of 1.18% [2] Financial Metrics - The Zacks Consensus Estimate for STERIS' fiscal 2025 earnings has increased by 0.9% to $9.10 per share, while the revenue estimate stands at $5.48 billion, indicating a 0.8% growth from fiscal 2024 [9] Challenges - Foreign currency risks pose a significant concern, with nearly 30% of revenues generated outside the U.S., leading to a negative impact of approximately $2.1 million in the fiscal second quarter due to currency fluctuations [7] - The competitive landscape is intense, with STERIS facing competition from both large companies with extensive product portfolios and smaller firms with limited offerings [8]